The development of newest technology of gene therapy PROGENTERM © was finalized in April 2016.
PROGENTERM © technology is the more effective technology than classic plasmid DNA, vectors and viral DNA.
Patented line of products for stimulation of the synthesis in eukaryotic cells
(PROGENTERM © TECHNOLOGY)
such protein molecules as:
- insulin-like growth factor (IGF)
- erythropoetin (EPO)
- somatotropin ( SMT-h)
- vascular endothelial growth factor (VEGF)
- activated mTORC1 for stimulation of protein synthesis in general
- antibodies to myostatin
- antibodies to viral infections
- nervous system regeneration factor
- High efficiency of DNA penetration in the cell.
- DNA doesn't integrate in the genome of the cell because of the special modification of the terminus.
- Duration of the work in the cells – no less than 7 days.